First targeted therapy slows glioma growth for years; limited access in Slovakia

A novel targeted therapy has demonstrated durable slowing of glioma growth over multiple years, marking a significant advance in brain tumor treatment. However, in Slovakia, only one patient has received the therapy so far, highlighting stark access disparities. The development is clinically meaningful but its broader impact depends on regulatory approvals and reimbursement decisions.